Advertisement
MED vs TOUR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MED is a Hold and TOUR is a StrongBuy.
Aroon Indicator for MED shows an upward move is likely
MED's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 100 similar instances where the Aroon Indicator showed a similar pattern. In 72 of the 100 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on MED as a result. In 58 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for MED just turned positive on October 14, 2026. Looking at past instances where MED's MACD turned positive, the stock continued to rise in 40 of 58 cases over the following month. The odds of a continued upward trend are 69%.
MED moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MED crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MED advanced for three days, in 146 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for MED moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
MED broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.729) is normal, around the industry mean (8.051). MED has a moderately low P/E Ratio (-5.498) as compared to the industry average of (10.423). Projected Growth (PEG Ratio) (0.230) is also within normal values, averaging (4.440). MED's Dividend Yield (0.515) is considerably higher than the industry average of (0.081). P/S Ratio (0.416) is also within normal values, averaging (1.645).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
TOUR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 19, 2026
TOUR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 37 cases where TOUR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where TOUR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for TOUR just turned positive on November 06, 2026. Looking at past instances where TOUR's MACD turned positive, the stock continued to rise in 37 of 52 cases over the following month. The odds of a continued upward trend are 71%.
Following a +0.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where TOUR advanced for three days, in 183 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TOUR as a result. In 84 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
TOUR moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for TOUR entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.055) is normal, around the industry mean (-0.351). P/E Ratio (1.563) is within average values for comparable stocks, (24.800). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.617). TOUR has a moderately high Dividend Yield (1.010) as compared to the industry average of (0.224). TOUR's P/S Ratio (0.643) is slightly lower than the industry average of (2.754).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. TOUR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
MED | TOUR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 86 | |
PRICE GROWTH RATING 1..100 | 43 | 71 | |
P/E GROWTH RATING 1..100 | 98 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TOUR's Valuation (2) in the Other Consumer Services industry is in the same range as MED (3) in the Specialty Stores industry. This means that TOUR’s stock grew similarly to MED’s over the last 12 months.
TOUR's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as MED (100) in the Specialty Stores industry. This means that TOUR’s stock grew similarly to MED’s over the last 12 months.
TOUR's SMR Rating (86) in the Other Consumer Services industry is in the same range as MED (94) in the Specialty Stores industry. This means that TOUR’s stock grew similarly to MED’s over the last 12 months.
MED's Price Growth Rating (43) in the Specialty Stores industry is in the same range as TOUR (71) in the Other Consumer Services industry. This means that MED’s stock grew similarly to TOUR’s over the last 12 months.
TOUR's P/E Growth Rating (97) in the Other Consumer Services industry is in the same range as MED (98) in the Specialty Stores industry. This means that TOUR’s stock grew similarly to MED’s over the last 12 months.
| MED | TOUR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | N/A |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 80% |
| Advances ODDS (%) | 3 days ago 61% | 15 days ago 79% |
| Declines ODDS (%) | 13 days ago 84% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 72% | 1 day ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MED’s FA Score shows that 1 FA rating(s) are green while TOUR’s FA Score has 1 green FA rating(s).
- MED’s FA Score: 1 green, 4 red.
- TOUR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MED’s TA Score shows that 6 TA indicator(s) are bullish while TOUR’s TA Score has 5 bullish TA indicator(s).
- MED’s TA Score: 6 bullish, 4 bearish.
- TOUR’s TA Score: 5 bullish, 2 bearish.
Price Growth
MED (@Personnel Services) experienced а +3.49% price change this week, while TOUR (@Consumer Sundries) price change was +0.42% for the same time period.
The average weekly price growth across all stocks in the @Personnel Services industry was -6.73%. For the same industry, the average monthly price growth was -8.29%, and the average quarterly price growth was -10.85%.
The average weekly price growth across all stocks in the @Consumer Sundries industry was -2.39%. For the same industry, the average monthly price growth was +3.78%, and the average quarterly price growth was +11.68%.
Reported Earning Dates
MED is expected to report earnings on Feb 23, 2027.
TOUR is expected to report earnings on Dec 04, 2026.
Industries' Descriptions
@Personnel Services (-6.73% weekly)Personnel Services comprise companies that provide staffing and human resources management solutions for businesses. Each company might be involved in one or more types of recruitment or employee solutions such as permanent or temporary staffing, career consulting, outsourcing, administrative services and many more. Some personnel services companies cater to large businesses, while some specialize in providing services to small/medium-sized organizations. These specialized services potentially expedite the process of getting the ‘right’ candidates and/or training them to meet the requirements of a business process. Some of the companies also cover other critical areas like internal auditing for a company. Robert Half International Inc., ManpowerGroup Inc. and Insperity, Inc. are examples of companies in the personnel services industry.
@Consumer Sundries (-2.39% weekly)Consumer sundries companies make products that usually do not have another classification, such as lawn and garden products, pest-control products, pet food and pet products like leashes, collars, and harnesses. Central Garden & Pet Company and Dogness (International) Corporation are examples of companies operating in this industry.
Advertisement
MED and
Correlation & Price change
A.I.dvisor indicates that over the last year, MED has been loosely correlated with EXPE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MED jumps, then EXPE could also see price increases.
| Ticker / NAME | Correlation To MED | 1D Price Change % | ||
|---|---|---|---|---|
| MED | 100% | +0.77% | ||
| EXPE - MED | 36% Loosely correlated | +2.37% | ||
| TNL - MED | 23% Poorly correlated | -0.37% | ||
| SABR - MED | 21% Poorly correlated | +6.21% | ||
| NCLH - MED | 20% Poorly correlated | +1.67% | ||
| TRIP - MED | 20% Poorly correlated | +5.36% | ||
More | ||||
TOUR and
Correlation & Price change
A.I.dvisor tells us that TOUR and MED have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TOUR and MED's prices will move in lockstep.
| Ticker / NAME | Correlation To TOUR | 1D Price Change % | ||
|---|---|---|---|---|
| TOUR | 100% | -1.27% | ||
| MED - TOUR | 22% Poorly correlated | +0.77% | ||
| SABR - TOUR | 20% Poorly correlated | +6.21% | ||
| EJH - TOUR | 20% Poorly correlated | +3.77% | ||
| TNL - TOUR | 18% Poorly correlated | -0.37% | ||
| BKNG - TOUR | 18% Poorly correlated | +0.60% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NUEM | 39.06 | 0.99 | +2.59% |
| Nuveen ESG Emerging Markets Equity ETF (NUEM) | |||
| TCHI | 18.96 | 0.23 | +1.24% |
| iShares MSCI China Multisector Tech ETF (TCHI) | |||
| BAMV | 37.02 | 0.37 | +1.02% |
| Brookstone Value Stock ETF (BAMV) | |||
| NULV | 55.07 | 0.25 | +0.45% |
| Nuveen ESG Large-Cap Value ETF (NULV) | |||
| CBXA | 22.79 | N/A | N/A |
| Calamos Bitcoin 90 Series Structured Alt Protection ETF - April | |||